Dabigatran

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Dabigatran
Accession Number
DB14726
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
  • Dabigatran
External IDs
BIBR 953 ZW / BIBR-953 / BIBR-953-ZW
Categories
UNII
I0VM4M70GC
CAS number
211914-51-1
Weight
Average: 471.521
Monoisotopic: 471.201887693
Chemical Formula
C25H25N7O3
InChI Key
YBSJFWOBGCMAKL-UHFFFAOYSA-N
InChI
InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34)21-4-2-3-12-28-21)14-19(20)30-22(31)15-29-18-8-5-16(6-9-18)24(26)27/h2-10,12,14,29H,11,13,15H2,1H3,(H3,26,27)(H,33,34)
IUPAC Name
3-[1-(2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-1,3-benzodiazol-5-yl)-N-(pyridin-2-yl)formamido]propanoic acid
SMILES
CN1C(CNC2=CC=C(C=C2)C(N)=N)=NC2=C1C=CC(=C2)C(=O)N(CCC(O)=O)C1=NC=CC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
(1,2,6,7-3H)Testosterone(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Dabigatran.
(R)-warfarinThe risk or severity of bleeding can be increased when (R)-warfarin is combined with Dabigatran.
(S)-WarfarinThe risk or severity of bleeding can be increased when (S)-Warfarin is combined with Dabigatran.
1-Testosterone1-Testosterone may increase the anticoagulant activities of Dabigatran.
18-methyl-19-nortestosterone18-methyl-19-nortestosterone may increase the anticoagulant activities of Dabigatran.
3,5-Diiodotyrosine3,5-Diiodotyrosine may increase the anticoagulant activities of Dabigatran.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Dabigatran.
4-Hydroxytestosterone4-Hydroxytestosterone may increase the anticoagulant activities of Dabigatran.
5beta-dihydrotestosterone5beta-dihydrotestosterone may increase the anticoagulant activities of Dabigatran.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Dabigatran.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D09707
ChemSpider
187412
BindingDB
50112086
RxNav
1546356
ChEBI
70752
ChEMBL
CHEMBL48361
ZINC
ZINC000001910616
PDBe Ligand
4CC
Wikipedia
Dabigatran
PDB Entries
4jn2 / 4yhi / 4yhk / 4yhm / 4yho

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1CompletedBasic ScienceHealthy Volunteers2
1CompletedTreatmentHealthy Volunteers11
1CompletedTreatmentInterstitial Lung Diseases (ILD) / Scleroderma1
1CompletedTreatmentImpaired kidney function1
1CompletedTreatmentThrombotic events1
1Not Yet RecruitingTreatmentMild Alzheimer's Disease / Mild Cognitive Impairment (MCI)1
2CompletedNot AvailableStaphylococcus Aureus Bacteraemia1
2CompletedNot AvailableVenous Thromboembolism1
2CompletedPreventionAtrial Fibrillation (AF)1
2CompletedTreatmentHeart Catheterization1
2CompletedTreatmentMinor Ischemic Stroke / Transient Ischaemic Attack (TIA)2
2Not Yet RecruitingTreatmentAnticoagulant-induced Bleeding1
2TerminatedTreatmentAtrial Fibrillation or Flutter / Thrombosis of Left Atrial Appendage1
2TerminatedTreatmentBleeding / Thrombotic events1
2Unknown StatusTreatmentCerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy1
2, 3TerminatedTreatmentPrimary Disease1
3Active Not RecruitingTreatmentMyocardial Injury After Noncardiac Surgery (MINS)1
3CompletedPreventionArthroplasty, Replacement, Knee / Thromboembolism1
3CompletedPreventionAtrial Fibrillation (AF) / Stroke1
3CompletedPreventionAtrial Septal Aneurysm / Migraine / Patent Foramen Ovale (PFO) / Stroke, Ischemic1
3CompletedPreventionVenous Thromboembolism1
3CompletedTreatmentAtrial Fibrillation (AF)1
3CompletedTreatmentThromboembolism1
3CompletedTreatmentHematomas1
3Not Yet RecruitingPreventionAtrial Fibrillation (AF) / Thromboembolism1
3Not Yet RecruitingPreventionStroke, Ischemic1
3Not Yet RecruitingTreatmentAtrial Fibrillation (AF)1
3Not Yet RecruitingTreatmentBleeding Post Cardiac Surgery / Indication for Anticoagulation1
3RecruitingPreventionAtrial Fibrillation (AF) / Cerebral Hemorrhage1
3RecruitingPreventionAtrial Fibrillation (AF) / Flutter, Atrial / Intracranial Hemorrhage, Hypertensive / Intracranial Hemorrhages / Intraventricular Hemorrhage / Microhaemorrhage / Small Vessel Cerebrovascular Disease / Subarachnoid Hemorrhage / Subdural haematoma1
3RecruitingPreventionAtrial Fibrillation (AF) / Stroke1
4Active Not RecruitingPreventionAtrial Fibrillation (AF)1
4Active Not RecruitingTreatmentAtrial Fibrillation (AF) / Valve Heart Disease1
4CompletedBasic ScienceAcute Coronary Syndromes (ACS) / Atrial Fibrillation (AF)1
4CompletedBasic ScienceVenous Thromboembolism1
4CompletedPreventionAtrial Fibrillation (AF)1
4CompletedTreatmentAtrial Fibrillation (AF)2
4CompletedTreatmentCoronary Heart Disease (CHD)1
4Not Yet RecruitingTreatmentAtrial Fibrillation (AF) / Ischemic Heart Disease1
4RecruitingPreventionAtrial Fibrillation (AF)1
4RecruitingPreventionBleeding / Left Atrial Appendage Closure / Stroke / Thrombotic events / Transient Ischaemic Attack (TIA)1
4RecruitingTreatmentAngiographically Confirmed Acute Massive Pulmonary Embolism Treated With Endovascular Mechanical Fragmentation and Thrombolytic Therapy / Dabigatran Etexilate / Pulmonary Embolism / Recurrence of DVT / Warfarin1
4RecruitingTreatmentAtrial Fibrillation (AF)2
4RecruitingTreatmentAtrial Fibrillation (AF) / Cardioembolic Events / Oral Anticoagulation1
4RecruitingTreatmentAtrial Fibrillation (AF) / Coronary Artery Disease1
4RecruitingTreatmentDiabetes1
4TerminatedDiagnosticAtrial Fibrillation (AF)1
4TerminatedTreatmentAcute Coronary Syndromes (ACS) / Atherosclerosis / Atrial Fibrillation (AF) / Coronary Heart Disease (CHD)1
4TerminatedTreatmentAtrial Fibrillation (AF) / Coronary Artery Disease1
4TerminatedTreatmentPulmonary Embolism1
4Unknown StatusNot AvailableAnticoagulant Overdosage / Anticoagulant-induced Bleeding / Hemorrhage / Thrombotic events1
4WithdrawnTreatmentCoronary Heart Disease (CHD) / Non ST Segment Elevation Myocardial Infarction (NSTEMI) / ST Elevation Myocardial Infarction (STEMI) / Stable Angina (SA) / Unstable Angina Pectoris1
Not AvailableActive Not RecruitingNot AvailableAnticoagulation1
Not AvailableActive Not RecruitingNot AvailableAtrial Fibrillation (AF)2
Not AvailableActive Not RecruitingHealth Services ResearchNeoplasms / Thrombosis, Venous1
Not AvailableCompletedNot AvailableAnticoagulants / Atrial Fibrillation (AF) / Pharmacoepidemiology1
Not AvailableCompletedNot AvailableAnticoagulation1
Not AvailableCompletedNot AvailableAtrial Fibrillation (AF)14
Not AvailableCompletedNot AvailableAtrial Fibrillation (AF) / Death / Major Bleeding / Myocardial Infarction / Stroke, Ischemic / Systemic Embolization1
Not AvailableCompletedNot AvailableAtrial Fibrillation (AF) / Hemorrhage1
Not AvailableCompletedNot AvailableAtrial Fibrillation (AF) / Strokes Thrombotic1
Not AvailableCompletedNot AvailableMajor Bleeding / Venous Thromboembolism1
Not AvailableCompletedNot AvailableStroke1
Not AvailableCompletedNot AvailableStroke, Ischemic1
Not AvailableCompletedNot AvailableStroke / Transient Ischaemic Attack (TIA)1
Not AvailableCompletedNot AvailableUnsuspected Pulmonary Embolism1
Not AvailableCompletedTreatmentCoronary Artery Disease1
Not AvailableEnrolling by InvitationNot AvailableDeep Venous Thrombosis / Pulmonary Embolism1
Not AvailableNot Yet RecruitingNot AvailableAnticoagulants Causing Adverse Effects in Therapeutic Use / Antiphospholipid Syndrome / Thrombotic events1
Not AvailableNot Yet RecruitingNot AvailableAtrial Fibrillation (AF)2
Not AvailableNot Yet RecruitingNot AvailableCerebral Vein Thrombosis / Ovarian vein thrombosis / Renal Vein Thrombosis / Retinal Vein Thrombosis / Splanchnic Vein Thrombosis1
Not AvailableNot Yet RecruitingBasic ScienceIdiopathic Pulmonary Fibrosis (IPF) / Interstitial Lung Diseases (ILD) / IPF1
Not AvailableRecruitingNot AvailableAnticoagulants and Bleeding Disorders / Venous Thromboembolism1
Not AvailableRecruitingNot AvailableAtrial Fibrillation (AF)1
Not AvailableRecruitingNot AvailableAtrial Fibrillation (AF) / Recurrent Venous Thromboembolism1
Not AvailableRecruitingNot AvailableCardioembolic Stroke1
Not AvailableRecruitingNot AvailableMyeloproliferative Neoplasms1
Not AvailableRecruitingPreventionAtrial Fibrillation (AF) / Stroke1
Not AvailableRecruitingSupportive CareAtrial Fibrillation (AF) / Hemorrhage / Periodontal Diseases1
Not AvailableRecruitingTreatmentAcute DVT of Lower Extremity1
Not AvailableRecruitingTreatmentAtrial Fibrillation (AF) / Stroke, Acute1
Not AvailableRecruitingTreatmentBlood Clots / Deep Vein Thrombosis / Malignancies / Pulmonary Embolism / Venous Thromboembolism1
Not AvailableRecruitingTreatmentIschaemic Stroke / Stroke, Ischemic1
Not AvailableTerminatedNot AvailableArthroplasty, Replacement / Venous Thromboembolism1
Not AvailableUnknown StatusNot AvailableStroke, Ischemic1
Not AvailableUnknown StatusSupportive CareBlood Loss / Osteoarthritis, Hip1
Not AvailableWithdrawnPreventionVenous Thrombembolic Events / Venous Thromboses1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0975 mg/mLALOGPS
logP2.37ALOGPS
logP0.077ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)3.18ChemAxon
pKa (Strongest Basic)12.52ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area150.22 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity143.26 m3·mol-1ChemAxon
Polarizability50.96 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on December 14, 2018 10:30 / Updated on March 01, 2020 21:55

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates